Company / Free Cash Flow per Share
Fulcrum Therapeutics, Inc. Free Cash Flow per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$953.03
FY2025
5-year range
-$2267.78 / -$40.27
FY2021-FY2025
Trend
-2266.7%
vs FY2024
Sector context
#191 of 192
Health Care
What the data says
Free Cash Flow per Share changed -2267% YoY in FY2025, a notable deviation from the 7-year average annual change of -288%.
Based on SEC 10-K filings.
-953.03 in FY2025.
Improved from $-1491.98 to $-953.03 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 192This company -$953.03 Sector average -$19.84
▼
-4703.7% below sector average
Key checks
Key Insights
- In FY2025, free cash flow per share decreased 2266.7% year-over-year.
- Ranks #191 out of 192 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2024.
- Lowest free cash flow per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$953.03 | -2266.7% |
| FY2024 | -$40.27 | +97.3% |
| FY2023 | -$1491.98 | +32.2% |
| FY2022 | -$2200.73 | +3.0% |
| FY2021 | -$2267.78 | -4.5% |
| FY2020 | -$2169.16 | +40.6% |
| FY2019 | -$3651.64 | +85.4% |
| FY2018 | -$25093.87 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026